Changes in β-amyloid (Aβ) and hyperphosphorylated tau (T) in brain and cerebrospinal fluid (CSF) precede Alzheimer's disease (AD) symptoms, making the CSF proteome a potential avenue to understand dis
Empirical evidence on cognitive function and its association with demographic, socioeconomic, health and behavioural factors among older adults in rural Bangladesh.
This systematic review examined the relationship between cognition and motor speech production in healthy older adults and those with mild cognitive impairment, analyzing 22 studies with 747 participants. Findings suggest that cognitive functions, particularly attention and executive abilities, are linked to motor speech performance, though evidence quality varies and gaps remain.
The article discusses advancements in using 3D models and human iPSC-derived microglia to study neurodevelopment and neurological disorders, highlighting their potential for understanding brain development, microglial functions, and disease mechanisms. It also explores various models, including organoids and xenotransplantation, and their applications in studying conditions like Alzheimer’s, Parkinson’s, and autism.
The article discusses the role of gut dysbiosis, bacterial amyloids, and metabolic diseases in the development and progression of Alzheimer's disease (AD). It highlights the bidirectional relationship between the gut microbiome, inflammation, and metabolic disorders, and how these interconnected pathways contribute to neurodegeneration. The review explores potential therapeutic strategies targeting the gut-brain-metabolic axis to mitigate AD progression.
The article provides a comprehensive review of the role of semaphorin 3A (Sema3A) in the pathogenesis and progression of Alzheimer's disease and other aging-related diseases. It discusses the expression patterns and mechanisms of action of Sema3A in various age-related disorders, including its involvement in oxidative stress, inflammatory responses, apoptosis, and synaptic plasticity.
Real-world evidence can supplement clinical trial data to optimize Alzheimer’s disease care by aiding early patient identification and assessing drug effectiveness and safety in everyday use in diverse clinical settings/populations. This information helps inform clinical practice guidelines and supports the development of tools for timely diagnosis and personalized treatment strategies.
This study identified over 2,000 proteins in cerebrospinal fluid that change at different stages before Alzheimer's symptoms appear, revealing key biological processes involved in the disease. Using machine learning, the researchers developed highly accurate models to predict Alzheimer's biomarker status, clinical diagnosis, and future disease progression.
This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by providing an overview of the cholinergic hypothesis of Alzheimer's Disease and potential innovations in cholinergic therapies.
This study identifies two CSF proteomic panels that accurately stage Alzheimer’s pathology, outperform current biomarkers, and predict dementia progression over 10 years, enhancing diagnosis and clinical trial stratification.
